Xcout Intel
Prilenia competitors & alternatives
The 12 closest competitors and alternatives to Prilenia among biotech companies — ranked by similarity to what Prilenia actually does, not by market-cap band.
Subscribe to see Prilenia’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Prilenia
Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead drug candidate, pridopidine, has been studied in Huntington’s disease and amyotrophic lateral sclerosis (ALS), serving patients with serious neurological conditions.
Prilenia at a glance
Prilenia is a biotech company headquartered in United States. Xcout recorded 4 job postings from Prilenia in the last 90 days.
Hiring at Prilenia
Xcout recorded 4 job postings from Prilenia in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Prilenia's hiring signals →
Top 12 Prilenia competitors
Ranked by semantic similarity — how close each company is to Prilenia by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Similar biotech company
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Biotechnology
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Similar biotech company
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Similar biotech company
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Biotechnology
Myrobalan Therapeutics is a pre-clinical biotechnology company headquartered in Medford, Massachusetts, focused on developing oral small molecule therapies for central nervous system and neurodegenerative diseases. The company targets novel mechanisms to create neurorestorative treatments for CNS disorders.
Similar biotech company
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Biotechnology
Neurona Therapeutics Inc. is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.
Biotechnology
Falcon Therapeutics, Inc., in association with Skyhawk Therapeutics, conducts global clinical trials for Huntington's disease. The company serves patients with Huntington's disease by evaluating the small molecule splicing modifier SKY-0515 to lower mutant huntingtin protein levels and slow disease progression.
Biotechnology
Delix Therapeutics is a privately held biopharmaceutical company headquartered in Boston, Massachusetts, focused on transforming the treatment of brain health through neuroscience.
Biotechnology
Arkuda Therapeutics is a biotechnology company developing small-molecule treatments for neurodegenerative diseases, with a focus on restoring lysosomal function and addressing progranulin-related disease biology. Its programs are aimed particularly at patients with frontotemporal dementia and other disorders involving lysosomal dysfunction.
Biotechnology
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York City, New York, focused on developing gene therapies for patients with neurodegenerative diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Prilenia and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Prileniaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →